Firm will receive $1 million over a year and a half.

Galapagos signed an agreement with CHDI Foundation to develop assays for drug discovery and evaluation of compounds as potential new therapeutics for Huntington’s disease (HD). Galapagos’ contract is valued at $1 million over 1.5 years.

Under the terms of the agreement, Galapagos’ service division, BioFocus, will develop a high-throughput screening assay in mouse neurons that will enable the identification of compounds that prevent neuronal dysfunction associated with HD. BioFocus DPI will also evaluate known compounds inhibiting enzymes that play key roles in HD.

These projects continue the collaboration between the organizations, which started in August 2005. “Galapagos demonstrated its capabilities in our target discovery collaboration, which encouraged us to choose BioFocus DPI for these new programs,” states Ignacio Munoz, vp of Biology at CHDI.

Previous articleAMRI Adds Non-GMP Manufacturing Services with Expansion of India Facility
Next articleEMD Serono Puts Down $30M for U.S. Rights to Theratechnologies’ Late-Stage Compound